CorMedix director receives 30,453 restricted shares

CorMedix Inc. director Stewart Robert A reported receiving 30,453 shares of common stock on a restricted basis at a price of $0.00 per share.

Accepted by SEC EDGAR 01/27/2026 - 09:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

CorMedix Inc. director Stewart Robert A reported receiving 30,453 shares of common stock on a restricted basis at a price of $0.00 per share. Following this grant, he beneficially owns 66,453 CorMedix shares directly.

The award consists of restricted stock units issued on January 26, 2026. Each unit converts into one share of common stock and will vest in full on January 26, 2027, provided he continues to serve through the vesting date.

Insider Trade Summary

Grant/Award: 30,453 shares

Grant/Award 1 txn

Insider Stewart Robert A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,453	$0.00	$0.00

Holdings After Transaction: Common Stock — 66,453 shares (Direct)

Footnotes (1)

1. F1. These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CorMedix Inc. (CRMD) report on this Form 4?

CorMedix reported that director Stewart Robert A received 30,453 restricted stock units of common stock at $0.00 per share. These are equity compensation awards rather than open-market purchases, reflecting stock-based pay instead of a cash transaction.

How many CorMedix (CRMD) shares does the director own after this transaction?

After the grant, director Stewart Robert A beneficially owns 66,453 shares of CorMedix common stock directly. This total includes the newly issued 30,453 restricted stock units, which each represent the right to receive one share upon vesting.

What are the vesting terms of the CorMedix (CRMD) restricted stock units?

The 30,453 restricted stock units were issued on January 26, 2026 and will vest in full on January 26, 2027. Vesting is conditioned on the director’s continued service with CorMedix through the vesting date.

Was any cash paid for the CorMedix (CRMD) shares reported in this Form 4?

No cash changed hands for this award. The Form 4 shows the director acquired 30,453 shares at a price of $0.00 per share, indicating the transaction is a stock-based compensation grant rather than a purchase in the market.

What type of security was granted to the CorMedix (CRMD) director?

The director received restricted stock units, each representing the right to receive one share of CorMedix common stock. These units were granted on January 26, 2026 and will convert into shares when they fully vest on January 26, 2027.

Is this CorMedix (CRMD) Form 4 transaction a purchase or compensation?

This transaction reflects equity compensation, not a market purchase. The director was granted 30,453 restricted stock units at $0.00 per share, consistent with stock awards typically used to compensate and align directors with shareholder interests over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stewart Robert A

(Last) (First) (Middle)

C/O CORMEDIX INC.

389 INTERPACE PKWY, SUITE 450

(Street)

PARSIPPANY NJ 07054

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		30,453	A	$0.00(1)	66,453	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units issued on January 26, 2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units will vest in full on January 26, 2027, subject to continued service on the vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Beth Zelnick Kaufman, attorney-in-fact	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.